COST EFFECTIVENESS OF ANTI-PD-1/PD-L1 TREATMENTS: SYSTEMATIC REVIEW OF PUBLISHED STUDIES

被引：0
|
作者：
Aggarwal, S. [1 ]
Topaloglu, O. [1 ]
Kumar, S. [2 ]
机构：
[1] NOVEL Hlth Strategies, Chevy Chase, MD USA
[2] Inst Global Policy, Washington, DC USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.187
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN110
引用
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
  • [31] Hodgkin lymphoma and imaging in the era of anti-PD-1/PD-L1 therapy
    Margarita Kirienko
    Martina Sollini
    Arturo Chiti
    Clinical and Translational Imaging, 2018, 6 : 417 - 427
  • [32] The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date
    Tsai, Katy K.
    Daud, Adil I.
    DRUGS, 2015, 75 (06) : 563 - 575
  • [33] Is anti-PD-1/PD-L1 immunotherapy sensitizing for conventional cancer therapies?
    Matias, M.
    Aspeslagh, S.
    Palomar, V.
    Lanoy, E.
    Dercle, L.
    Even, C.
    Ferte, C.
    Hollebecque, A.
    Marabelle, A.
    Massard, C.
    Soria, J-C.
    Postel-Vinay, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [34] Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
    Kudo, Masatoshi
    LIVER CANCER, 2020, 9 (06) : 629 - 639
  • [35] Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies
    Liu, Shufang
    Niu, Wenquan
    JAMA ONCOLOGY, 2020, 6 (02) : 298 - 299
  • [36] Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?
    Sundararajan, Srinath
    Vogelzang, Nicholas J.
    FUTURE ONCOLOGY, 2015, 11 (16) : 2299 - 2306
  • [37] Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
    Sibaud, Vincent
    Meyer, Nicolas
    Lamant, Laurence
    Vigarios, Emmanuelle
    Mazieres, Julien
    Delord, Jean Pierre
    CURRENT OPINION IN ONCOLOGY, 2016, 28 (04) : 254 - 263
  • [38] Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
    Chen, Gang
    Huang, Alexander C.
    Zhang, Wei
    Zhang, Gao
    Wu, Min
    Xu, Wei
    Yu, Zili
    Yang, Jiegang
    Wang, Beike
    Sun, Honghong
    Xia, Houfu
    Man, Qiwen
    Zhong, Wenqun
    Antelo, Leonardo F.
    Wu, Bin
    Xiong, Xuepeng
    Liu, Xiaoming
    Guan, Lei
    Li, Ting
    Liu, Shujing
    Yang, Ruifeng
    Lu, Youtao
    Dong, Liyun
    McGettigan, Suzanne
    Somasundaram, Rajasekharan
    Radhakrishnan, Ravi
    Mills, Gordon
    Lu, Yiling
    Kim, Junhyong
    Chen, Youhai H.
    Dong, Haidong
    Zhao, Yifang
    Karakousis, Giorgos C.
    Mitchell, Tara C.
    Schuchter, Lynn M.
    Herlyn, Meenhard
    Wherry, E. John
    Xu, Xiaowei
    Guo, Wei
    NATURE, 2018, 560 (7718) : 382 - +
  • [39] Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
    Ma, Long
    Jin, Gang
    Yao, Keying
    Yang, Yi
    Chang, Ruitong
    Wang, Wenhao
    Liu, Jiawei
    Zhu, Zijiang
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [40] Influence of lactate in resistance to anti-PD-1/PD-L1 therapy: Mechanisms and clinical applications (Review)
    Zeng, Yi
    Huang, Yu
    Tan, Qiaoyun
    Peng, Ling
    Wang, Jian
    Tong, Fan
    Dong, Xiaorong
    MOLECULAR MEDICINE REPORTS, 2025, 31 (02)
12345